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Summary. Background: Procarboxypeptidase U (proCPU, TAFI, proCPB2), the zymogen of CPU, which is a potent antifibrinolytic enzyme and a modulator of inflammation, has previously been investigated in plasma of stroke patients, but so far, no information on the proCPU levels in cerebrospinal fluid (CSF) during acute ischemic stroke (AIS) is available. Objectives: This case-control observational study investigates proCPU in CSF of AIS patients compared with controls with an intact blood-brain barrier (BBB) and evaluates the relationship of CSF/plasma proCPU ratios with stroke parameters. Methods: A sensitive HPLC-based enzymatic assay was used to determine proCPU levels in CSF of non-thrombolyzed patients in the hyperacute phase (< 24 h after onset) of AIS (n = 72). Individuals (n = 32) without stroke, an intact BBB and no apparent abnormalities in biochemical and microbiological tests, served as controls. Relations between the CSF/plasma proCPU ratio and (i) stroke severity, (ii) stroke progression/recurrence, (iii) stroke outcome and (iv) BBB dysfunction (CSF/serum albumin ratio) were assessed. Results: Mean (SEM) proCPU levels were elevated in the CSF of stroke patients compared with controls 
Introduction
Procarboxypeptidase U (proCPU, TAFI, proCPB2) circulates in plasma as a zymogen and can be activated by plasmin, thrombin and the thrombin-thrombomodulin complex, resulting in the formation of active carboxypeptidase U (CPU, TAFIa, CPB2) [1, 2] . CPU is a potent antifibrinolytic enzyme and is suggested to modulate inflammation through cleavage of anaphylatoxins C3a and C5a, bradykinin and osteopontin [3, 4] . CPU is characterized by its profound thermal instability resulting in conformational changes and loss of function [5] . Because of its antifibrinolytic capacities, the interest in the (pro)CPU system as a target in the treatment of thrombotic events such as acute ischemic stroke (AIS) is rising.
It was reported that proCPU-antigen plasma levels are elevated in the hyperacute phase of ischemic stroke (< 24 h after symptom onset) compared with controls [6, 7] ; however, these studies were compromised by the proCPU-325 polymorphism-dependent reactivity of the assays used [8] . Recent studies showed no difference in the proCPU activity levels on admission compared with controls [9, 10] . Brouns et al. observed a decrease in plasma proCPU levels in the first 72 h after stroke onset, reflecting ongoing proCPU activation, that correlated with stroke severity, progression and outcome in non-thrombolyzed AIS patients [9] . Furthermore, a decreased efficacy of thrombolytic therapy in patients with increased plasma CPU levels was found and recently, increased CPU+CPUi levels in plasma were linked to poor clinical outcome in AIS patients [10] [11] [12] .
Baseline levels of proCPU have been detected in cerebrospinal fluid (CSF) of controls [13, 14] but so far no information on proCPU and CPU levels in CSF of AIS patients and their potential relationship to stroke parameters is available. In the current study we investigate proCPU in undiluted CSF of patients with AIS and controls.
Methods

Stroke patients
This study is part of the Middelheim's Interdisciplinary Stroke Study (ZNA Middelheim Hospital, Antwerp, Belgium, [2005] [2006] [2007] [2008] , a project on the clinical, biochemical, neuroimaging, neuropsychological and electrophysiological evaluation of patients with AIS or transient ischemic attack (TIA). On admission, ischemic stroke was confirmed by CT or MRI. ProCPU plasma levels were determined in 136 non-thrombolyzed patients and were previously reported [9] . The current study focuses on 72 of these patients with AIS (n = 58) or TIA (n = 14) in whom lumbar puncture was performed within 24 h after symptom onset. This study was conducted according to the Declaration of Helsinki and approved by the Ethics Committees of ZNA Antwerp and the University of Antwerp.
Controls
Between January and May 2016, diagnostic leftover CSF samples of 32 adult patients with an intact blood-brain barrier (BBB) were collected in the Antwerp University Hospital. These patients underwent lumbar puncture for suspicion of central nervous system infection, neurological symptoms, memory problems or suspicion of neurodegenerative diseases, even though no biochemical or microbiological abnormalities in the CSF were identified. The primary selection criterion for BBB permeability was the age-corrected CSF/serum albumin ratio (AR) (n = 11); if the AR was not available (n = 21), the total protein concentration in CSF (< 60 mg dL À1 ) was used to select a control population with an intact BBB [15] .
Evaluation of stroke etiology, severity, progression and outcome
The subtype of AIS was classified according to the TOAST criteria and was dichotomized in cardioembolic and non-cardioembolic etiology [16] . The National Institutes of Health Stroke Scale (NIHSS) was assessed on admission and after 24 h, 72 h and 7 days by trained physicians to quantify neurological deficit. Patients with an NIHSS score > 7 on admission were considered to have a severe stroke. Stroke progression was evaluated according to the European Progressing Stroke Study Criteria (EPSS) [17] . Stroke outcome was assessed by the modified Rankin Scale (mRS) 3 months after the event; poor outcome was defined as an mRS score > 3 [18] . After 12 months, stroke recurrence was assessed.
Sample collection and biochemical analysis Lumbar puncture was followed by fractionated sampling in multiple collection tubes. Subsequently, a full work-up of the CSF was performed in the hospital's clinical laboratory. Traumatic taps were excluded if red blood cell count was over 5 lL
À1
. CSF samples for proCPU determination were aliquoted and stored at À80°C. Before analysis of proCPU, samples were centrifuged (10 000 9 g, 10 min).
The determination of proCPU in plasma as well as the AR in this population was previously described [9, 19] . In the current study, an in-house enzymatic assay with increased selectivity and a shorter turnaround time was used for the determination of proCPU levels in CSF [13, 20] . The assay was initially developed for the measurement of proCPU in plasma after dilution (409) of the samples. As we expected low proCPU levels, CSF samples were not diluted. BBB dysfunction was assessed by the age-corrected AR; cut-off values were 7 9 10 À3 for patients aged under 40 years, 8 9 10 À3 for patients between 40 and 60, 9 9 10 À3 for patients between 60
and 80 and 10 9 10 À3 for patients over 80.
Statistical analysis
Statistical computations and data plotting were performed using GraphPad Prism version 7.01. Differences between normally distributed or sufficiently large (n > 20)
groups were analyzed with a t-test for independent samples; a Mann-Whitney U-test was used for smaller or not normally distributed groups. ProCPU ratios in relation to stroke parameters are shown as median [interquartile range; IQR] unless indicated otherwise. The relations between proCPU levels in CSF and those in plasma and between proCPU ratios and parameters for stroke or BBB dysfunction were evaluated by bivariate correlations. The Pearson coefficient (r) was used for continuous parameters and Spearman's rho (q) for ordinal variables.
Results and discussion
The current study is the first to report on proCPU in CSF of stroke patients (n = 72) compared with controls (n = 32). Patient and stroke characteristics are summarized in Table 1 . Previously, Lin et al. and Matsumoto et al.
reported on brain-derived full-length CPB2 transcripts and shorter alternatively spliced transcripts without carboxypeptidase activity [21, 22] . Baseline levels of proCPU in CSF have been detected in controls and elevated levels were found in patients with traumatic brain injury and bacterial meningitis [13, 14] . Antovic et al. could not detect proCPU antigen in CSF, most probably because of extensive dilution of the samples before analysis [23] . We modified our existing in-house plasma proCPU assay to be applicable in CSF [20] . The modified assay has an excellent linearity (R² = 0.9998) and recovery (94.4-104.8%) after spiking of purified proCPU (0-15
In the hyperacute phase of ischemic stroke (< 24 h after symptom onset), mean (SEM) proCPU levels in CSF were higher compared with controls (4.36 (0.23) U L À1 vs. 3.50 (0.23) U L À1 ; t-test, P < 0.05) (Fig. 1) .
Plasma concentrations of proCPU in the (sub)acute phase of AIS were previously determined by our research group [9] . On admission to the hospital, the mean (SEM) proCPU plasma level of the current study cohort of 72 patients was 959 (19) U L À1 . The mean (SD) time interval between blood sampling and lumbar puncture was 0.7 (1.0) h; the interval between symptom onset and lumbar puncture was 9.0 (6.4) h. None of these intervals influenced proCPU levels in CSF or plasma (r = À0.085 and 0.076, respectively; P > 0.05). ProCPU levels in CSF of non-thrombolyzed stroke patients are 200-2259 lower compared with those in plasma and we observed no correlation between levels in plasma and CSF in the stroke population (r = 0.170; P > 0.05; data not shown).
BBB dysfunction
During AIS, the BBB is frequently compromised, which is associated with acute complications (e.g. cerebral edema). The long-term consequences of BBB dysfunction during AIS are diverse and the key mechanisms are not completely elucidated yet [24] . Brouns et al. indicated that the CSF/serum albumin ratio (AR) is a reliable biomarker for BBB dysfunction in hyper acute stroke and that the extent of BBB disruption relates to stroke severity, unfavorable stroke evolution and poor long-term outcome [19] . In the current study cohort, which is part of the same population as the one investigated by Brouns and coworkers, the AR was determined for 67 patients and we evaluated the correlation between the AR and the CSF/plasma proCPU ratio. We found an apparent correlation between the proCPU ratio and the AR ( Fig. 2A ; r = 0.65; P < 0.0001). As assessed by the age-corrected AR, proCPU ratios were higher in patients with BBB dysfunction (n = 11) compared with patients with an intact BBB (n = 56) ( 
Stroke parameters
As displayed in Fig. 3(A) , the CSF/plasma proCPU ratio was increased in patients with progressive stroke ((6.0 [4.2-6.9]) 9 10
À3
) compared with non-progressive stroke ((3.9 [2.7-5.4]) 9 10 À3 ; Mann-Whitney U, P < 0.01).
Increased proCPU ratios were also observed in patients with poor outcome (Fig. 3B ) assessed by the mRS score and mortality ((4.0 [2.8-5.0]) 9 10 À3 for mRS 0-3 vs. À3 in deceased patients; Mann-Whitney U, P < 0.01 and P < 0.05, respectively). We observed statistically significant correlations of the proCPU ratio with stroke progression (q = 0.30, P < 0.01) and stroke outcome that was assessed by the mRS score and mortality at month 3 (q = 0.30, P < 0.05 and q = 0.31, P < 0.01, respectively). Mean (SEM) proCPU ratios in patients with cardioembolic stroke did not differ significantly from those in . ProCPU in CSF of stroke patients was significantly higher compared with that of controls (*t-test for independent samples; P < 0.05). The increase of proCPU in CSF of patients with stroke progression and unfavorable outcome is most likely secondary to BBB dysfunction. It was shown that patients with BBB dysfunction are prone to stroke progression and poor outcome [19] . Additionally, our data show a strong correlation of the proCPU ratio with BBB dysfunction. Furthermore, after excluding patients with BBB dysfunction, the increase in proCPU levels was no longer observed in stroke patients compared with controls ( t-test P > 0.05). It is also doubtful that a mean increase of proCPU in CSF of approximately 1 U L À1 could have a significant influence on pathophysiology, although higher local concentrations cannot be excluded. The low circulating levels of proCPU in CSF, even after complete conversion into active CPU, will probably be too low to exert an antifibrinolytic effect in the brain, especially considering the fact that CPU attenuates fibrinolysis through a threshold-dependent mechanism that is dependent on the tissue-type Plasminogen Activator (tPA) concentration [25] . As the major components of the plasminogen activating system (including tPA) are strongly expressed in the central nervous system [26] , a high CPU threshold value is to be expected. From the moment the CPU activity falls under the threshold level, fibrinolysis accelerates exponentially and becomes uncontrollable by the residual CPU.
The fibrinolytic pathway and its effector enzyme, plasmin, are also closely linked to the activation and regulation of the complement system. The proCPU system modulates inflammation through cleavage of anaphylatoxins such as C3a and C5a [27] . The complement system plays a distinct role in cerebrovascular inflammation after ischemic stroke and plasma levels of C3a and C5a are increased in the (sub)acute phase of ischemic stroke [28, 29] . Furthermore, an increase in C3 and C3a plasma levels in patients with cardioembolic stroke was linked with unfavorable long-term outcome [30] . It is therefore arguably possible that increased proCPU levels in CSF may influence acute neuro-inflammation during AIS.
A possible limitation of the study is that the stroke and control populations were not age and sex matched. Furthermore, correction of the proCPU concentrations was not performed because age-and sex-dependent reference intervals for proCPU have not been established. This problem is partly solved by measuring CSF/plasma ratios for the stroke population. Matched plasma samples, however, were not available for the controls as we used leftover clinical CSF samples. In the future it might also be interesting to look for active CPU in CSF, but this would require a special sampling procedure using PPACK and aprotinin [31] . 
Conclusion
In conclusion, this study is the first to survey proCPU levels in CSF of stroke patients. During hyperacute ischemic stroke, proCPU is increased in CSF compared with controls. CSF/plasma proCPU ratios correlate with stroke progression and outcome, but these findings are most likely secondary to BBB dysfunction in the hyperacute phase of ischemic stroke. 
